AzTrials
AzTrials

Multiple SclerosisDBLNCT06068582

Don't be Late! Postponing Cognitive Decline and Preventing Early Unemployment in People With Multiple Sclerosis

A study testing Strenghtening the brain and Strengthening the mind in people with Multiple Sclerosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Read more about this study

Who is it for?
Ages 18 to 67 years
Conditions the study is for
Multiple Sclerosis
What is being tested?
Strenghtening the brain and Strengthening the mind
Could I receive a placebo?
No, everyone receives an active treatment
How many people
270 participants
Where
1 siteNetherlands
Study dates
16 Apr 2023to Sep 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 67 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Confirmed MS diagnosis according to the McDonald 2017 criteria
  • Age between 18 and 67
  • No changes in disease modifying therapy prior to inclusion (i.e., no changes in last 3 months) - this criterion only applies at inclusion to ensure participants are in a stable situation at the start of the study and for follow-up measures, changes in treatment will be registered but will not result in exclusion from the study
  • no current relapse or steroid treatment in the six weeks prior to study visits
  • presence of mild cognitive deficits (at least one test with a Z-score of -1.0 to -1.99 below norm scores of healthy controls on the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery
  • being able to participate in an exercise intervention (i.e., EDSS < 6.0)
  • fulfilling safety criteria for MRI (no metal inside body, not pregnant, no claustrophobia)

Who cannot join

  • presence of neurological (other than MS) and psychiatric disorders
  • a current or history of drug or alcohol abuse
  • being unable to speak or read Dutch
  • currently on sick leave for a period of 6 weeks or longer
  • currently pregnant

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Netherlands1 site, 1 recruiting
  • Amsterdam University Medical Centers, location VUmc

    Amsterdam

    Recruiting

Other trials in Netherlands

About this study

The goal of this randomized controlled trial is to compare the effectiveness of two innovative interventions aimed at preventing cognitive decline and work-related problems to enhanced usual care in improving quality of life in people with multiple sclerosis. Secondary objectives are:

  • to compare the effectiveness of the investigated interventions in improving cognitive, psychological, and work functioning, and in enhancing the brain's functional network
  • to examine which factors (i.e., baseline cognitive, psychological, work, and brain MRI-parameters) are predictive of the response to the investigated interventions
  • aim to qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice

Participants will follow the intervention for four months, with follow-up measurements at six months after intervention and 12 months after intervention.

Read the detailed description

Background Up to 65% of the people with multiple sclerosis (PwMS) develop cognitive deficits that severely affect daily life functioning and PwMS' quality of life. Moreover, approximately 65% of all patients end up unemployed within five years after diagnosis. Current treatments mostly focus on symptom management and return to work, which may be too late. It is hypothesized that timely interventions will help prevent or delay cognitive decline and work-related problems in PwMS, thereby improving quality of life.

Objectives

Primary Objective:

To compare the effectiveness of the investigated interventions with enhanced usual care in improving quality of life.

Secondary Objectives:

  1. To compare the effectiveness of the investigated interventions in improving cognitive, psychological and work functioning, and in enhancing the brain's functional network.
  2. To examine which factors (i.e. baseline cognitive, psychological, work and brain MRI-parameters) are predictive of the response to the investigated interventions.
  3. To qualitatively reflect on the process and outcome of the investigated interventions considering the perspectives of relevant stakeholders to allow for smooth and successful implementation in clinical practice.
  4. To compare the cost-effectiveness of the investigated interventions.

Material and methods A randomized controlled trial with three arms and three follow-up visits over a total time period of 16 months. During these visits researchers will gather information from questionnaires, neuropsychological examination, MRI and blood sampling. All participants (N= 240) have a confirmed MS diagnosis according to the McDonald 2017 criteria, have subclinical cognitive impairment and are aged between 18 and 67. Participants will be randomly assigned to one of the three arms (N=90 in each arm). Interviews will be conducted with 12-15 participants from both interventions, 10-12 sport coaches, 8-12 work coaches and 10-12 supervisors from the workplace.

'Strengthening the brain' (4 month-program) consists of weekly 30 minutes 1-on-1 exercise and lifestyle coaching in combination with two moments per week unsupervised exercises at home and a home-based online computerized cognitive training. 'Strengthening the mind' (4 month-program) consists of biweekly contact with work coaches who are all diagnosed with MS themselves. 'Enhanced usual care' entails an appointment with a researcher in addition to usual care.

Results The primary outcome is change in quality of life as measured with the 36-item Short Form. Several secondary outcomes will be collected: cognitive, psychological, cost-effectiveness, structural- and functional brain, neurological, physiological, and qualitative measures.

Being tested
Strenghtening the brain, Strengthening the mind
Keywords
Multiple Sclerosis, Cognition, Exercise, Employment, Prevention, Health-related Quality of Life
Medical subject headings
Multiple Sclerosis, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Strenghtening the brainBehavioural

    Lifestyle intervention containing physical exercise, lifestyle coaching, and cognitive training. The programme contains weekly 30 minutes 1-on-1 fitness and lifestyle coaching with two moments of exercise at home for 20 minutes. Online computerized cognitive training will be done for 60 minutes per week.

  • Strengthening the mindBehavioural

    Work-focused intervention combining the capability approach and the participatory approach. Together with a work-coach who has been diagnosed with MS themselves, participants will assess important work values, discover challenges participants are facing, think of solutions for these challenges, develop a plan of action and implement these solutions.

Study groups in NCT06068582
Study groupRoleWhat they receive
Strengthening the brainExperimentalParticipants receive 30 minutes of 1-on-1 fitness training, dietary advice, and mental coaching, in addition to twice 20 minutes fitness at home, and 60 minutes of cognitive training each week for four months.
Receives: Behavioral: Strenghtening the brain
Strengthening the mindExperimentalPartiicpants receive biweekly 1-on-1 coaching by a trained work-coach who has MS to identify challenges at work and implement solutions. It is completed when satisfactory solutions have been implemented for all challenges or after four months.
Receives: Behavioral: Strengthening the mind
Enhanced usual careNo interventionParticipants receiving general information about cognitive impairment in MS and following care as usual for four months.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Quality of Life

    Quality of life assessed using the 36-item Short Form. Item-scores are summed and transformed into a total score that ranges 0-100. Higher score corresponds with better quality of life.

    Measured: Baseline, Month 4, Month 10, and Month 16

Secondary outcomes (35)
  1. Information processing speed

    Information processing speed is assessed using the Symbol Digit Modalities Test (SMDT). The total responses made in 90 seconds is administered. Higher amount of correct responses equals better information processing speed.

    Measured: Baseline, Month 4, Month 10, and Month 16

  2. Information processing speed

    Information processing speed is assessed using the Paced Auditory Serial Addition Test (PASAT). The total correct answers given, out of 60, is administered. Higher amount of correct responses equals better information processing speed.

    Measured: Baseline, Month 4, Month 10, and Month 16

  3. Verbal fluency

    Verbal fluency is assessed using the Dutch adaptation of the Controlled Oral Word Association Test; Dutch Letter Fluency Test. Total number of correct words will be administered. Higher score corresponds with better verbal fluency.

    Measured: Baseline, Month 4, Month 10, and Month 16

  4. Spatial Processing

    Spatial Processing is assessed using the Judgement of Line Orientation. Total correct responses, with maximum 30, will be administered. Higher score corresponds with better spatial processing.

    Measured: Baseline, Month 4, Month 10, and Month 16

  5. Verbal New Learning and Memory

    New Learning and Memory is assessed using the California Verbal Learning Test, second edition (CVLT-II). Direct recall on the CVLT-II will be administered using number of correctly remembered items over learning trials 1-5. Delayed recall on CVLT-II will be administered using number of correctly remembered items 20 minutes after learning trail 5. Maximum scores for direct recall, delayed recall, and recognition are set at 80, 16, and 44, respectively. Higher score equals better verbal learning and memory.

    Measured: Baseline, Month 4, Month 10, and Month 16

  6. Visual New Learning and Memory

    New Learning and Memory is assessed using the Brief Visuospatial Memory Test-Revised (BVMT-R). Direct recall on BVMT-R will be administered using number of correctly remembered items over learning trials 1-3. Delayed recall on BVMT-R will be administered using number of correctly remembered items 25 minutes after learning trail 3. Maximum scores for direct recall, delayed recall, and recognition are set at 36, 12, and 12, respectively. Higher score equals better visual learning and memory.

    Measured: Baseline, Month 4, Month 10, and Month 16

  7. Executive Function

    Executive Function is assessed using the Delis-Kaplan Executive Function System. Total correct sorts will be administered, with a maximum of 16 sorts. A higher score suggests better executive functioning.

    Measured: Baseline, Month 4, Month 10, and Month 16

  8. Self-Reported Cognitive Functioning

    Self-Reported Cognitive Functioning is assessed using the Multiple Sclerosis Neuropsychological Screening Questionnaire. Maximum score of 70 can be reached, with a score of 27 or higher indicating presence of neuropsychological problems.

    Measured: Baseline, Month 4, Month 10, and Month 16

  9. Work Participation and Productivity

    Work Participation and Productivity is assessed using the Work Productivity and Activity Impairment Questionnaire: General Health, which administers the effect of health-problems on ability to work. Scores are calculated as percentages, with higher numbers indicating greater impairment and less productivity.

    Measured: Baseline, Month 4, Month 10, and Month 16

  10. Work Difficulties

    Work Difficulties are assessed using the Multiple Sclerosis Work Difficulties Questionnaire. The questionnaire consists of 23 items, which can be grouped into three subscales: psychological/cognitive barriers, physical barriers, and external barriers. The maximum score of each subscale is 100, with higher scores indicating higher perceived difficulties. Total score consists of an average of the three subscale scores.

    Measured: Baseline, Month 4, Month 10, and Month 16

  11. Capability to carry out Work Activities

    Capability to carry out Work Activities is assessed using the Capability Set for Work Questionnaire. This questionnaire evaluates for seven valued work aspects whether, A) it is important to the worker, B) their work offers sufficient opportunities to do it, and C) it can be achieved, on a 5-point Likert scale.

    Measured: Baseline, Month 4, Month 10, and Month 16

  12. Quality of Working Life

    Quality of Working Life is assessed using the Quality of Working Life Questionnaire for Cancer Survivors. The questionnaire consists of five subscales: meaning of work, perception of the work situation, atmosphere in the work environment, understandings and recognition in the organisation, and problems due to health situation. The overall score and sum scores of the subscales are calculated with a standardised score 0-100. Higher score corresponds with better quality of working life.

    Measured: Baseline, Month 4, Month 10, and Month 16

  13. Grey Matter Volume of the Brain

    Grey Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.

    Measured: Baseline, Month 4, and Month 16

  14. White Matter Volume of the Brain

    White Matter Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.

    Measured: Baseline, Month 4, and Month 16

  15. Total Brain Volume

    Total Brain Volume will be determined using FSL-SIENAX, after lesion filling on the 3DTI.

    Measured: Baseline, Month 4, and Month 16

  16. Volumes of Deep Grey Matter Structures

    Volumes of Deep Grey Matter Structures will be determined using FIRST.

    Measured: Baseline, Month 4, and Month 16

  17. Cortical Thickness

    Cortical Thickness will be determined using Freesurfer.

    Measured: Baseline, Month 4, and Month 16

  18. White Matter Integrity

    White Matter Integrity will be determined using Diffusion Tensor Imaging

    Measured: Baseline, Month 4, and Month 16

  19. Functional Connectivity

    Functional Connectivity will be determined using Resting-State fMRI

    Measured: Baseline, Month 4, and Month 16

  20. Regional Functional Activation

    Regional Functional Activation will be determined using Task-Based fMRI

    Measured: Baseline, Month 4, and Month 16

  21. Fatigue

    Fatigue will be assessed using the Checklist Individual Strength. The questionnaire consists of 20 items, scored on a 7-point Likert scale. Fatigue is a subscale of the questionnaire, and is scored by adding the scores of the items, where a higher score corresponds with more fatigue.

    Measured: Baseline, Month 4, Month 10, and Month 16

  22. Mood and Anxiety

    Mood and Anxiety will be assessed using the Hospital Anxiety and Depression Scale. The questionnaire consists of 14 items on a 4-point Likert scale. The range of scores is 0-21 where a higher score equals more complaints of anxiety and depression.

    Measured: Baseline, Month 4, Month 10, and Month 16

  23. Resilience

    Resilience will be assessed using the Connor Davidson Resilience Scale. Total score ranges 0-100, with higher scores reflecting greater resilience.

    Measured: Baseline, Month 4, Month 10, and Month 16

  24. Perceived Level of Stress

    Perceived Level of Stress will be assessed using the Perceived Stress Scale. Total score ranges 0-40, with higher scores indicating higher perceived stress.

    Measured: Baseline, Month 4, Month 10, and Month 16

  25. Social Mindfulness

    Social Mindfulness will be assessed using the SoMi paradigm by van Doesum et al. (2013). Choices that are made are scores as mindful (1) or unmindful (0). Final score will be computed by averaging the scores over all decisions, resulting in a number between 0 (unmindful) and 1 (mindful).

    Measured: Baseline, Month 4, Month 10, and Month 16

  26. Social Participation

    Social Participation will be assessed using the PROMIS 'Ability to Participate in Social Roles and Activities' item bank. The questionnaire consists of eight items that can be scored on a 5-point Likert scale. Higher scores indicate better ability to participate in social roles and activities.

    Measured: Baseline, Month 4, Month 10, and Month 16

  27. MS-related disability

    MS-related disability will be assessed using the Expanded Disability Status Scale. This scale ranges from 0.0 to 10.0, where a higher score indicates worse disability.

    Measured: Baseline, Month 4, Month 10, and Month 16

  28. Balance

    Balance will be assessed using the Mini-BESTest. The test contains 14 items where a total score of 28 points can be achieved, where a score <19 induces an increased risk of falling.

    Measured: Baseline, Month 4, and Month 16

  29. Walking Speed

    Walking Speed will be assessed using the Timed 25-Foot Walk.

    Measured: Baseline, Month 4, and Month 16

  30. Endurance

    Endurance will be assessed using the Shuttle Walk Test according to the protocol of Singh et al. (1992).

    Measured: Baseline, Month 4, and Month 16

  31. Grip Strength

    Grip Strength will be assessed using a JAMAR hand-held dynamometer.

    Measured: Baseline, Month 4, and Month 16

  32. Upper Limb Dexterity

    Upper Limb Dexterity will be assessed using the 9-Hole Peg Test and the Purdue Pegboard Test.

    Measured: Baseline, Month 4, and Month 16

  33. Lost Productivity Costs

    Lost Productivity Costs will be assessed using the iMTA Productivity Cost Questionnaire. The questionnaire consists of three modules measuring absenteeism, presenteeism, and productivity loss from unpaid work.

    Measured: Baseline, Month 4, Month 10, and Month 16

  34. Societal Costs including Healthcare, Patient, and family

    Societal Costs will be assessed using the iMTA Medical Consumption Questionnaire.

    Measured: Baseline, Month 4, Month 10, and Month 16

  35. Quality Adjusted Life Years

    Quality Adjusted Life Years will be assessed using the EuroQol five-dimensional Questionnaire. The questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Higher scores indicate more problems considering the dimensions.

    Measured: Baseline, Month 4, Month 10, and Month 16

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Oct 2023
  2. Study start16 Apr 2023
  3. Primary completionSep 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Investigator, Outcomes assessor
Enrolment
270 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06068582
Sponsor's protocol ID
NL82007.018.23
Other IDs
NWA.1292.19.064
Acronym
DBL
Status last verified
Mar 2025
First submitted
25 Aug 2023
Last updated
3 Apr 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data relating to the main outcomes will be shared in online repository. Coded data will be published in an online scientific archive for the purpose of future research, in line with Open Science practices, and for the verification of findings. These data would not be traceable as they are not linked in any way to personal data. MRI data will be stored in OSF and other platforms that may accommodate the large capacity of the data set.

Publications

  • Aarts J, Saddal SRD, Bosmans JE, de Groot V, de Jong BA, Klein M, Ruitenberg MFL, Schaafsma FG, Schippers ECF, Schoonheim MM, Uitdehaag BMJ, van der Veen S, Waskowiak PT, Widdershoven GAM, van der Hiele K, Hulst HE; Don't be late! consortium. Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol. BMC Neurol. 2024 Jan 15;24(1):28. doi: 10.1186/s12883-023-03513-y.

    PubMed 38225561

Questions about this trial

What is this clinical trial studying?

A study testing Strenghtening the brain and Strengthening the mind in people with Multiple Sclerosis, run by Amsterdam UMC, location VUmc at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jip Aarts (+31 71 5275081, j.aarts@fsw.leidenuniv.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Quality of Life (time frame: Baseline, Month 4, Month 10, and Month 16). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06068582, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in